Abstract:
INTRODUCTION
Giant Cell (temporal) Arteritis (GCA) is a chronic, systemic vasculitis, with a distinct tropism for large and medium-sized arteries with well-developed elastic membranes. The epidemiology of GCA suggests striking differences in disease risk among ethnic groups, with the highest incidence rates found in Scandinavian and other people of Northern European descent, irrespective of their place of residence [1 -5] . Globally, the incidence of GCA is around 27 per 100,000 in persons over 50 years of age [6] . Corticosteroids are the mainstay of therapy. Prompt diagnosis and initiation of therapy is critical to prevent complications such as partial visual loss or blindness and other vascular complications [7 -11] . The average duration of corticosteroid therapy in GCA is 2-3 years, although lifelong treatment may be required in some patients [8, 12 -15] . duration of steroids treatment and decrease the frequency and/or intensity of patient experienced side effects.
MATERIALS AND METHODS
The databases searched were; Medline®, Cochrane library and EMBASE® using the keywords <steroid sparing effects>, <methotrexate>, <mycophenolate mofetil>, <cyclophos-phamide>, <azathioprine>, <anti-TNF agents>, <abatacept>, <selective T cell co-stimulation modulator> and <tocilizumab> and <Giant Cell Arteritis>. The limits applied were from 2000 onwards and articles in the English language, and adult population. Relevant natural language and controlled vocabulary terms were selected and combined. Where possible, articles were restricted to systematic reviews, RCTs or case series.
RESULTS AND DISCUSSION

Variations in the Optimal Treatment Strategies for GCA
In a large, representative cohort of real-world patients seen in routine clinical practice of rheumatologists across the United States of America, treatment patterns were reviewed using data from electronic medical records and other sources in an ongoing and continuous updating manner. These patients met the definition of at least two GCA-related diagnosis codes within a 1-year period, between 2013 and 2016. Amongst 1567 patients with a mean age of 72+10 years, 78% were Caucasian and 78% were females. The mean follow-up period was 24 months with an average of 12 Rheumatology clinic visits. There were 14% of all patients treated with more than one agent concurrently, and 85% received corticosteroids. This study demonstrated that there was wide variation in treatment practices where 22% of patients treated with methotrexate, 8% with hydroxychloroquine, 5% with aspirin, 5% with tocilizumab, and 3.5% with azathioprine [6] . This also reflects the lack of clarity around the value of additional steroidsparing agents to avoid [6] corticosteroids.
Relapsing and Refractory GCA
The traditional view of GCA as a corticosteroid-responsive disease is not always accurate or predictable; a spectrum of severity and extent exists. In observational cohort studies, relapses were reported in 34-62% of patients, with 15-20% achieving long-term sustained remission with corticosteroids alone [22] . Based on treatment response, GCA patients can be divided into four subgroups; in-remission, relapsed, refractory, and corticosteroid intolerant [3] . The last three groups exhibit the greatest unmet need for adjunctive therapy [22] . A critical review of the literature published in Clinical and Experimental Rheumatology [23] revealed five case series with large cohorts. These suggested that 40-48% of GCA patients require additional immunosuppressive agents to achieve remission and to taper their corticosteroid intake.
Methotrexate and Steroid-Sparing Effect
Methotrexate (MTX) efficacy and safety was evaluated in patients with GCA enrolled in three randomized clinical trials. These reported inconsistent efficacy, but reductions in relapse rate and in overall corticosteroids exposure [24 -26] . In a meta-analysis of individual patient data from these trials, it was found that adjunctive low-dose MTX reduced both relapse risk and corticosteroids exposure, though the frequency and severity of AEs were not reduced [27, 28] . Adjunctive MTX may reduce cumulative corticosteroids doses by 20% [25] and relapses by 35% (28) in GCA. Similar beneficial effects were observed to reduce corticosteroids dose and a reduction in relapses [23] . Based on a systematic analysis of clinical trial data, the use of MTX as a steroid-sparing strategy may be considered for patients at high risk for corticosteroid-induced AEs at disease outset. It may also be useful for patients whose disease course is protracted and who are at risk for recurrent relapses and corticosteroid-induced AEs [29, 30] .
Mycophenolate Mofetil
In a retrospective study (n=65 GCA patients), patients were divided into 3 treatment groups; prednisolone alone, prednisolone with methotrexate, and prednisolone with mycophenolate (MMF). No significant difference was shown between the groups. The study concluded that MMF is as effective as MTX and prednisolone alone in the treatment of Large Vessel Vasculitis (LVV). However, the patient group was small which limits the generalisation of this finding. Additionally, there was no randomisation to the treatment group; treatment choice was based on clinician preference. There was potential bias in that patients perceived to be more difficult to treat may have been given MMF or MTX in addition to prednisolone, and there were a higher proportion of patients with LVV compared to GCA in the MMF and MTX treated groups [31 -34] .
Azathioprine
A two-centre retrospective study was designed to describe the use of azathioprine in GCA and to evaluate its steroidsparing effect. Of the 28 patients included, 21 responded to the combination of azathioprine and prednisolone [35] . At 1 year of follow-up from the initiation of azathioprine and a daily dose of prednisone, 18 patients (64%) were still in sustained response, asymptomatic, and showed no increase in acute phase response laboratory markers. Three patients (11%) experienced a relapse during azathioprine treatment. The mean daily dose of prednisone was 25.4 mg at the time of initiation of azathioprine, and 4.7 mg at 1 year of treatment, suggesting a good steroid-sparing effect [35] . Treatment cessation was required in 7 out of 10 patients who experienced azathioprinerelated serious side effects. It was concluded that azathioprine may be an alternative treatment for patients with GCA requiring prolonged high dose corticosteroids therapy or developing severe corticosteroid related side effects [35] .
Cyclophosphamide
Data from 19 patients treated with cyclophosphamide (CYC) were retrospectively analysed. In 15 of the 19 patients, CYC had been administered after the failure of high doses of corticosteroids, or experiencing a relapse during medium to high dose corticosteroids therapy, with or without MTX [36] . CYC was used as the initial treatment in corticosteroid naive patients (4 of the 19 patients). All of the participants were also diagnosed with type 2 diabetes. During the 6-12 months follow-up, 15 of the 19 patients remained in remission. Corticosteroids were suspended in 6 of the 15 patients, and a dose of 5 mg/day of prednisone was continued in 9 patients. Relapse occurred in 4 of the 15 patients who sustained remission, usually 12 months after CYC was ceased. The cessation or reduction of their corticosteroid daily dose or reduction to 5 mg/day of prednisone took place within the first 6 months of follow-up after the initiation of CYC in 10 of the 15 patients. Ten adverse events were registered in nine patients, with recovery soon after the suspension of CYC or dose reduction [36] . However, one death occurred due to acute hepatitis. The disappearance of inflammatory infiltrate was demonstrated in one patient when temporal artery biopsy was repeated 3 months after CYC therapy. This study concluded that CYC could represent a useful option for patients requiring prolonged medium-to high-dose of corticosteroid therapy and at high risk of corticosteroids-related side effects (36).
Anti-TNF Agents and their Steroid-Sparing Effect in GCA
A systematic review [37] was conducted to evaluate the efficacy and safety of infliximab and etanercept in LVV. This review concluded that infliximab was not more effective than corticosteroids in inducing remission in GCA patients, but it was effective in inducing remission and in steroid-sparing in corticosteroid refractory Takayasu's arteritis. The review concluded that etanercept has a role as a steroid-sparing agent in GCA with corticosteroid related sever`1`e adverse effects and is effective in inducing remission in corticosteroid refractory GCA [37].
Abatacept (Selective T cell Co-Stimulation Modulator) and Steroid-Sparing in GCA
Abatacept, a selective T cell co-stimulation modulator [38] , was recently evaluated in a multicentre, randomized, double-blind (phase 2) trial of 49 patients with GCA who received a standardized prednisone tapering regimen [20] . Patients' selection criteria were temporal artery abnormality, a biopsy demonstrating vasculitis, and characteristic changes of large-vessel stenosis or aneurysm on arteriography. Additionally, those with large-vessel involvement underwent MRI of the aorta and branches initially and at 6-month intervals. At 12 months, the relapse-free rate was significantly higher in the abatacept group than in the placebo group (48 vs 31%; P = 0.049), and a longer median duration of remission was achieved with abatacept (9.9 vs 3.9 months; P = 0.023). Despite the small number of patients with large-vessel involvement in this study population, the findings suggest that abatacept may be an efficacious treatment option for reducing relapse in patients with GCA, but comparative studies will be required to determine its place in therapy.
IL-6R Antagonist (Tocilizumab) and Steroid-Sparing Effect in GCA
Interleukin (IL)-6 contributes to the pathogenesis of GCA and represents a possible target for therapy. A retrospective study of 12 patients, with relapsing GCA history, were treated with monthly infusions of the IL-6 receptor (IL-6R) antagonist tocilizumab (TCZ). The average daily prednisone dose decreased from 24 mg (95% CI 15-33.5) at the time of TCZ initiation to by the time of last evaluation (P = 0.01) [39] . The mean follow-up of this cohort since diagnosis was 37 months. Out of all the patients who received TCZ, 7 patients were in disease remission until the end of follow-up for a mean time of 17.5 months (range 8-26), and 5 patients experienced a flared after an average of 11 months of therapy (range 2-25). It was concluded that TCZ led to a significant decrease in the flare rate and requirement for corticosteroid use in the study sample. These findings supported that TCZ is a steroid-sparing agent during treatment and in GCA remission [39, 40] . GiACTA, a randomized, double-blind, placebo-controlled trial, evaluated TCZ effectiveness in achieving sustained, corticosteroid -free remission. This was the first trial to employ a blinded, variabledose corticosteroid-tapering regimen [38] . The study concluded that TCZ was not only highly effective in maintaining disease remission induced by the combination of TCZ and prednisone, but also that IL-6R blockade has a pronounced steroid-sparing effect for patients [41] . The trial had 4 arms: 1) TCZ SC 162 mg weekly plus 6-month prednisone taper; 2) TCZ SC 162 mg every other week plus 6-month prednisone taper; 3) prednisone only at 6-month taper; and 4) prednisone only at 12-month taper. Remission was sustained in 56% of the patients treated with TCZ for 52 weeks in the weekly group and in 53% in the 'every other week' groups, as compared with 14% in the 6 months prednisone taper group and 18% in the 12 months prednisone taper group (P<0.001 for the comparisons of either TCZ treatment with prednisone only groups). Serious adverse events occurred in 15% of the patients in the group that received TCZ weekly, 14% of those in the group that received TCZ every other week, 22% in the prednisone 6-moth taper group, and 25% in the 12 months prednisone taper group. Anterior ischemic optic neuropathy developed in one patient in the group that received TCZ every other week [31] . Table 1 summarizes all agents used for steroid-sparing and the type of evidence available and recommendation for steroidsparing in GCA. *Levels of evidence: I-Systematic review of all relevant RCT's or an n=1RCT, II-Randomised trial or observational study with dramatic effect, III-Non-randomised controlled cohort/follow up study(observational), IV-Case-series, case-control studies, or historically controlled studies, V-mechanism-based reasoning (expert opinion, based on physiology, animal or laboratory studies). *Grades: A-consistent level I studies, B-Consistent level II or III studies or extrapolations from level I studies, C-level IV studies or extrapolations from level 2 or 3 studies, D-level V evidence or troubling inconsistent or inconclusive studies of any level.
CONCLUSION AND RECOMMENDATION
At the time of writing, there was no British Society for Rheumatology guidance although this may be revised soon. We analysed 13 studies ( Table 2) . There were two studies that did not support the additive value of the use of steroid-sparing agents. Five studies concluded that due to their small sample size, they recommend conducting further larger studies and 11 studies concluded that there was significant value to the use of steroid-sparing agents in side-effect reduction and clinical outcomes improvement.
Considering all the evidence available for choosing the most appropriate steroid-sparing agent in GCA, a large number of studies favoured TCZ. There is good evidence that it can safely be used for:
Steroid-sparing Induction of remission Maintenance of remission Less frequent flare-ups
The next best agent for steroid-sparing effect appears to be MTX. There is good quality evidence that supports the use of MTX to reduce flares in relapsing GCA and help in reducing the corticosteroid dose and adverse effects.
Amongst anti-TNF agents, use of etanercept can be an option in corticosteroid refractory GCA to induce remission. Abatacept, a selective T cell co-stimulation modulator had shown promise in reducing relapse in GCA in RCTs involving a small number of GCA patients.
Immunosuppressants like azathioprine, mycophenolate, and cyclophosphamide may be used in refractory GCA or large vessel vasculitis patients as third-line agents. 68.0, (interquartile range (IQR) 17.7, n=37) , for the MMF treated group 70.8 (IQR 28.7, n=20) and for the MTX treated group 67.8 (IQR 20.4 n=8) . Median AOC CRP was highest in the group treated with prednisolone alone (58.9, IQR 34.5) compared to MMF (43.8, IQR 26.5) and MTX (49.3 IQR 67.5) 
Case presentation
The mean follow-up of this cohort since diagnosis was 37 months (range 17-70) . Eight subjects had failed at least one immunosuppressant (methotrexate, azathioprine, cyclophosphamide, infliximab, adalimumab and etanercept) , and four had contraindications for the use of GC. TCZ (4mg/kg, n =3 and 8mg/kg, n =9) was given for a mean period of 16 months (range 6-27 at the time of TCZ initiation to by the time of last evaluation (P =0.01 
